Status:
TERMINATED
Persantine: Variation in Response Trial
Lead Sponsor:
UConn Health
Collaborating Sponsors:
United States Department of Defense
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
21+ years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to understand why different people respond differently to the medication Persantine. The effects of Persantine will be evaluated by performing echocardiograms, b...
Detailed Description
Participants will receive three doses of Persantine intravenously for the research study. Before and after receiving the Persantine doses, patients will have an echocardiogram and coronary artery bloo...
Eligibility Criteria
Inclusion
- Patients \> 21 years old
- Patient undergoing cardiac catheterization with planned PTCA or with a significant coronary lesion of either the LAD or Circumflex
Exclusion
- Theophylline or oral Persantine use in 24hrs
- Second or third degree AV block, or sick sinus syndrome without a functioning pacemaker
- Active asthma or bronchospasm
- Patients with severe hepatic insufficiency
- Patients experiencing an acute transmural infarction at the time of the index visit
- Conditions that are known to affect resistive vessel function or myocardial flow
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00763009
Start Date
September 1 2002
End Date
July 1 2009
Last Update
April 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCONN Health Center
Farmington, Connecticut, United States, 06030